文献速递冠心病血脂与心血管预防

司美格鲁肽对SELECT研究中已确诊心血管疾病且超重或肥胖患者高敏C反应蛋白的影响:预设二次分析

Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.
PubMed 文献 · Circulation · 2026-08-18

基线hsCRP在两组相似(几何均值1.96 vs 1.91 mg/L),可预测MACE风险;司美格鲁肽降低hsCRP(104周-37.8%)并在各hsCRP亚组降低MACE风险,hsCRP降低与MACE风险下降相关,建模提示炎症减少部分贡献了司美格鲁肽的获益。

要点

  • 基线hsCRP水平可预测SELECT人群未来MACE风险。
  • 司美格鲁肽在104周降低hsCRP达37.8%,且在各hsCRP亚组均降低MACE风险。
  • 司美格鲁肽相关的hsCRP降低独立于LDL-C、他汀使用及入组动脉粥样硬化标准。

核心结论

  • SELECT中基线与治疗后的hsCRP数据支持炎症是此类一般治疗良好的动脉粥样硬化性心血管病且超重或肥胖但无糖尿病患者心血管风险的潜在预后因素。
  • 司美格鲁肽相比安慰剂在SELECT中观察到的MACE减少可能部分涉及炎症的降低。

研究设计与样本

  • 评估基线hsCRP是否预测MACE风险,并采用包括Cox建模在内的多种方法分析hsCRP变化与首次MACE时间、基线体重、体重减轻及其他临床指标的关系(104、208周)。

主要发现

  • 基线hsCRP几何均值司美格鲁肽组1.96 mg/L、安慰剂组1.91 mg/L,可预测未来MACE。
  • 基线hsCRP <2、2-<10、≥10 mg/L亚组间MACE风险递增,包括与心血管死亡和全因死亡的显著关联。
  • 司美格鲁肽降低hsCRP(104周-37.8%)并在所有hsCRP亚组降低MACE风险。
  • 司美格鲁肽组hsCRP相对基线降幅越大与体重减轻越多相关,但hsCRP下降先于大幅体重减轻,在第4和8周即明显,且见于无体重减轻者。
  • 司美格鲁肽相关的hsCRP变化独立于低密度脂蛋白胆固醇水平、他汀使用及动脉粥样硬化性心血管病入组标准;hsCRP降低可预后MACE风险降低。

临床怎么用

  • 在此类无糖尿病的动脉粥样硬化性心血管病且超重或肥胖患者中,基线hsCRP可用于辅助风险评估。
  • 司美格鲁肽降低hsCRP并降低MACE风险,抗炎效应可能部分解释其心血管获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity), among 17 604 patients with known atherosclerotic cardiovascular disease and overweight or obesity, but not diabetes, randomization to the glucagon-like peptide-1 receptor agonist semaglutide significantly reduced the primary outcome of major adverse cardiovascular events (MACE; cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) compared with placebo (mean follow-up, 39.8 months). Inflammation, as indicated by plasma hsCRP (high-sensitivity C-reactive protein) level, is implicated as a biomarker predicting cardiovascular risk in obesity and atherosclerotic cardiovascular disease. SELECT provides a unique opportunity to study the relationship among hsCRP, obesity, weight loss, and MACE outcomes in semaglutide versus placebo groups. METHODS: In this prespecified SELECT substudy, we evaluated whether baseline hsCRP levels predicted MACE risk and examined the relationships between changes in hsCRP levels and time to first MACE, baseline body weight, weight loss, and other clinical measures among treatment groups over time (104, 208 weeks) using multiple approaches, including Cox modeling. RESULTS: Baseline hsCRP level, which was similar in the semaglutide (geometric mean 1.96 mg/L) and placebo (geometric mean 1.91 mg/L) groups, was prognostic of future MACE. The risk of MACE increased across baseline hsCRP level <2, 2-<10, and ≥10 mg/L subgroups, including significant associations with cardiovascular and all-cause death. Semaglutide reduced hsCRP levels (-37.8% [104 weeks]) and risk of MACE across all hsCRP subgroups. Greater reductions in ratio-to-baseline hsCRP with semaglutide were associated with greater weight loss, but preceded major weight loss, evident by 4 and 8 weeks, and occurred among those without weight loss. Semaglutide-associated changes in hsCRP were independent of low-density lipoprotein cholesterol levels, statin use, and atherosclerotic cardiovascular disease entry criteria. hsCRP reductions were found to be prognostic of decreased risk of MACE. Modeling suggests decreased inflammation as contributing in part to the benefits seen with semaglutide in SELECT. CONCLUSIONS: In SELECT, hsCRP data at baseline and in response to treatment with semaglutide support inflammation as a potential prognostic factor associated with cardiovascular risk in these generally well-treated patients with atherosclerotic cardiovascular disease and overweight or obesity but not diabetes. These findings suggest that the MACE reduction observed with semaglutide versus placebo in SELECT may have partially involved a decrease in inflammation. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03574597.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Plutzky J, Bogdański P, Colhoun HM, et al. Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis. Circulation. 2026. PMID: 42610271. doi:10.1161/CIRCULATIONAHA.125.074482

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。